Physician profile
Lawrence O Ogbechie
NPI 1003868217
$8,621.95
in general payments reported to CMS, 2019-2025
17 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $425 · 2021: $672 · 2022: $1,423 · 2023: $1,887 · 2024: $1,544 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,286 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,285.95 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,824.98 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $1,120.01 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,041.62 | 2021-2025 | Caplyta |
| Alkermes, INC. | $913.14 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $801.46 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $638.84 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $619.90 | 2019-2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $446.17 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $363.15 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $250.72 | 2021-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Almatica Pharma LLC | $183.76 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $170.26 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $114.92 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $49.56 | 2019-2021 | |
| Hologic Sales and Service, LLC | $46.29 | 2025 | Thinprep 2000 Processor, Aptima |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.00 | 2021 | |
| Neuronetics, INC. | $17.17 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Ogbechie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.